Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug-resistant TB news

Show

From To
Frequently asked questions about the implementation of the new WHO recommendation on the use of the shorter MDR-TB regimen

These FAQs address key points regarding the implementation of the WHO treatment guidelines for drug-resistant tuberculosis, 2016 update, in TB and TB/HIV programmes.

Published
15 June 2016
From
World Health Organization
The Worst Superbug? Tuberculosis

The ground-breaking publication of Lord Jim O'Neill's global Review on Antimicrobial Resistance (AMR) is the wake-up call the world desperately needs. Have no doubts: the 'superbugs' that develop antimicrobial resistance are a threat of immense proportions and have a potential impact of 10 million deaths a year by 2050 as antibiotic efficacy dwindles.

Published
20 May 2016
From
Huffington Post UK
Rapid diagnostic test and shorter, cheaper treatment signal new hope for multidrug-resistant tuberculosis patients

New WHO recommendations aim to speed up detection and improve treatment outcomes for multidrug resistant tuberculosis (MDR-TB) through use of a novel rapid diagnostic test and a shorter, cheaper treatment regimen.

Published
12 May 2016
From
World Health Organization
STREAM clinical study first to include bedaquiline to test shortened treatment regimens for multidrug-resistant III in Phase III trial

Stage 2 of the trial aims to reduce MDR-TB treatment from 24 months to 6 or 9 months.

Published
18 April 2016
From
International Union Against Tuberculosis and Lung Disease
Battling TB and other outbreaks “staff, stuff, space, and systems ” still lacking

Paul Farmer first saw multidrug-resistant tuberculosis in the early 1990s in Haiti, from where he smuggled a patient’s sputum sample to test for drug resistance in Boston. Months later, Partners in Health co-founder Dr. Jim Kim with other colleagues discovered a cluster of fifty MDR-TB patients in a squatter settlement of 100,000 in Lima, Peru. That’s when they started to talk to the world about the emergence of MDR-TB.

Published
24 March 2016
From
Science Speaks
Just 2% of people with the severest cases of drug-resistant TB currently have access to new, more effective treatments

Two years after two new drugs to treat tuberculosis—the first in over 50 years—were conditionally approved for use, only 2% of the 150,000 people who need them have been able to access them, according to Médecins Sans Frontières (MSF).

Published
24 March 2016
From
Médecins Sans Frontières
USAID announces new partnerships to combat MDR-TB

At last week’s launch of the National Action Plan for Combating Multidrug-Resistant Tuberculosis, the U.S. Agency for International Development announced expanded partnerships with Janssen, the maker of bedaquiline, the first tuberculosis drug to be produced since the 1950s, and Cepheid, maker of the GeneXpert rapid diagnostic test for drug-resistant tuberculosis.

Published
13 January 2016
From
Science Speaks
TAG’s Response to the U.S. Action Plan for Combating Multidrug Resistant Tuberculosis

Treatment Action Group (TAG) welcomes the release of the Obama Administration’s National Action Plan for Combating Multidrug-Resistant Tuberculosis. Strengthening the domestic and global and research efforts to address multidrug-resistant tuberculosis (MDR-TB) are critical to ending the suffering this preventable, curable disease needlessly causes. However, the targets set forth in this plan are not ambitious enough to effectively stop the spread of MDR-TB.

Published
11 January 2016
From
Treatment Action Group
First new TB drugs in half a century reach just 2% of people who need them

MSF calls for companies to make new drugs to treat drug-resistant TB available and affordable.

Published
04 December 2015
From
MSF
New cohort study shows promise of dramatically shorter treatment option for multidrug - resistant TB

New findings from clinical studies presented at the 46th Union World Conference on Lung Health show promise for a shorter, 9 -month treatment course for MDR-TB. The standard treatment length recommended by the World Health Organization requires 24 months of treatment.

Published
03 December 2015
From
46th Union World Conference on Lung Health
← First12345...18Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close